Hematologic Malignancy
Childhood Lymphoma
CI-CAN-00000716Explore in graph →
PediatricHematologic13 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000716Explore in graph →
Clinical trials
98 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (10)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | recruiting | Phase 1 | 54 | Sumithira VasuOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03478462 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) |
| active not recruiting |
| Phase 1 |
| 30 |
| Cellectar Biosciences, Inc.INDUSTRY |
| 3 |
| Mar 18, 2026 |
| clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 26, 2026source: clinicaltrials